CytomX CTMX
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$3.58M (9 inflow days, 11 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 46.6% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 15.89% to 20.77% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| FMR | Mutual Fund | 2026/Q3 | +1,621,245 | 15.8% |
| Squarepoint OPS LLC | Hedge Fund | 2026/Q3 | +1,368,921 | 0.7% |
| BlackRock | Mutual Fund | 2026/Q3 | +910,985 | 8.5% |
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +817,086 | 0.5% |
| BNP Paribas Financial Markets SNC | Private Company | 2026/Q3 | +793,567 | 0.4% |
| Peak Financial Advisors, LLC | Mutual Fund | 2026/Q3 | +462,061 | 0.2% |
| Barclays Bank Plc | Private Company | 2026/Q3 | +414,796 | 0.2% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +414,735 | 2.3% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +305,234 | 0.9% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +374,478 | 0.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +12,331,542 | 8.1% |
| Kynam Capital Management, LP | Hedge Fund | 2026/Q3 | +6,690,000 | 10.0% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +6,083,828 | 5.4% |
| Bank of America Corporation | Public Company | 2026/Q3 | +4,879,832 | 6.9% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +2,612,104 | 2.1% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 2 Aug 2026 | Alejandra Carvajal | Chief Legal Officer | Other Acquisition | +100,000 | – | 100,000 |
| 2 Aug 2026 | Alejandra Carvajal | Chief Legal Officer | Other Derivative Acquisition | +450,000 | $3.17 | 450,000 |
| 23 Jul 2026 | Charles Fuchs | Independent Director | Other Derivative Acquisition | +118,000 | $3.24 | 118,000 |
| 16 Jun 2026 | Elaine Jones | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | Mani Mohindru | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | James Meyers | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | Matthew Young | Lead Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | Halley Gilbert | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | Alan Ashworth | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | Zhen Su | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 14 Jun 2026 | Christopher Ogden | SVP, CFO & Secretary | Open Market Disposition | -1,624 | $3.05 | 128,075 |
| 16 Mar 2026 | Sean McCarthy | Chairperson & CEO | Open Market Disposition | -118,969 | $6.42 | 714,580 |
| 16 Mar 2026 | Yu-Waye Chu | Senior VP & Chief Medical Officer | Open Market Disposition | -21,279 | $6.42 | 39,613 |
| 16 Mar 2026 | Marcia Belvin | Senior VP & Chief Scientific Officer | Open Market Disposition | -31,492 | $6.42 | 164,927 |
| 16 Mar 2026 | Christopher Ogden | SVP, CFO & Secretary | Open Market Disposition | -19,323 | $6.42 | 123,866 |
| 1 Feb 2026 | Sean McCarthy | Chairperson & CEO | Other Acquisition | +210,000 | – | 698,750 |
| 1 Feb 2026 | Sean McCarthy | Chairperson & CEO | Other Derivative Acquisition | +980,000 | $6.09 | 980,000 |
| 1 Feb 2026 | Rachael Lester | Chief Business Officer & Senior VP | Other Acquisition | +20,000 | – | 20,000 |
| 1 Feb 2026 | Rachael Lester | Chief Business Officer & Senior VP | Other Derivative Acquisition | +50,000 | $6.09 | 50,000 |
| 1 Feb 2026 | Yu-Waye Chu | Senior VP & Chief Medical Officer | Other Acquisition | +75,000 | – | 206,000 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 45,246,966 | 20.8% | 12.0 |
| 15 Oct 2026 | 42,790,446 | 19.6% | 13.8 |
| 30 Sep 2026 | 40,813,393 | 18.7% | 8.7 |
| 15 Sep 2026 | 38,639,220 | 17.7% | 9.3 |
| 31 Aug 2026 | 33,512,293 | 15.4% | 11.8 |
| 14 Aug 2026 | 34,619,999 | 15.9% | 15.9 |
No comments yet — be the first to weigh in on CTMX.
Sign in to join the discussion.